Jefferies Group recently announced the initiation of research coverage on Alnylam Pharmaceuticals and assigned a "Hold" rating to its stock.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ-Drax wins contract for over 1 gigawatt data center project
OPay backed by SoftBank suddenly halts US IPO, regulatory inquiries become the biggest uncertainty
Nigerian digital financial platform OPay announced the suspension of its IPO after revealing pricing, citing a regulatory inquiry. The company stated that the listing may be restarted in the coming months.
Morgan Stanley: AI capital expenditure may reach 10 to 15 trillions USD in the next 10 years
Morgan Stanley stated that capital expenditure in the artificial intelligence (AI) sector could reach $10-15 trillions over the next decade.
Crypto prices
More
